# Clinical trial results:
# COR-1, an anti-ß1 receptor antibody cyclopeptide in heart failure: a phase II, multicentre, randomised, double-blind and placebo controlled study with parallel groups

## Summary

| | |
|---|---|
| EudraCT number | 2010-022579-68 |
| Trial protocol | DE |
| Global end of trial date | 28 August 2013 |

### Results information

| | |
|---|---|
| Result version number | v1 (current) |
| This version publication date | 15 July 2016 |
| First version publication date | 15 July 2016 |

## Trial information

### Trial identification

| | |
|---|---|
| Sponsor protocol code | COR-1/02; 54452840HFA2002 |

### Additional study identifiers

| | |
|---|---|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT01391507 |
| WHO universal trial number (UTN) | - |

Notes:

### Sponsors

| | |
|---|---|
| Sponsor organisation name | CorImmun GbmbH |
| Sponsor organisation address | Johnson & Johnson Platz 1, Neuss, Germany, 41470 |
| Public contact | Clinical Registry group, Janssen-Cilag International N.V, +31 715242166, ClinicalTrialsEU@its.jnj.com |
| Scientific contact | Clinical Registry group, Janssen-Cilag International N.V, +31 715242166, ClinicalTrialsEU@its.jnj.com |

Notes:

### Paediatric regulatory details

| | |
|---|---|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

## Results analysis stage

| | |
|---|---|
| Analysis stage | Final |
| Date of interim/final analysis | 28 August 2013 |
| Is this the analysis of the primary completion data? | Yes |
| Primary completion date | 28 August 2013 |
| Global end of trial reached? | Yes |
| Global end of trial date | 28 August 2013 |
| Was the trial ended prematurely? | No |

Notes:

## General information about the trial

Main objective of the trial:

The primary objective is to investigate whether intravenous COR-1 administration every 4 weeks in addition to standard therapy enhances cardiac function at rest in patients with heart failure due to DCM, compared to standard therapy alone after 6 months.

Protection of trial subjects:

Safety data, including but not limited to adverse events, serious adverse events, treatment discontinuation, changes in vital signs, electrocardiogram (ECG) parameters, echocardiography parameters, circulating anti-1-AR autoantibodies, laboratory values, and use of concomitant medications were summarized in summary tables and/or frequency tabulations were analysed throughout the study.

Background therapy: -

Evidence for comparator: -

| | |
|---|---|
| Actual start date of recruitment | 25 October 2011 |
| Long term follow-up planned | Yes |
| Long term follow-up rationale | Safety |
| Long term follow-up duration | 1 Years |
| Independent data monitoring committee (IDMC) involvement? | Yes |

Notes:

## Population of trial subjects

### Subjects enrolled per country

| | |
|---|---|
| Country: Number of subjects enrolled | Germany: 36 |
| Worldwide total number of subjects | 36 |
| EEA total number of subjects | 36 |

Notes:

### Subjects enrolled per age group

| | |
|---|---|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 23 |

| | |
|---|---|
| From 65 to 84 years | 13 |
| 85 years and over | 0 |

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

A total of 36 participants were enrolled in the study. Ten participants were randomized to placebo and 8, 6, and 12 participants were randomized to JNJ-54452840 20 mg, 80 mg, and 160 mg, respectively.

### Period 1

| | |
|---|---|
| Period 1 title | Overall (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Double blind |
| Roles blinded | Subject, Investigator, Carer, Assessor |

### Arms

| | |
|---|---|
| Are arms mutually exclusive? | Yes |
| **Arm title** | Placebo |

Arm description:

Matching placebo (0.9 percent sodium chloride solution) was administered intravenously in addition to the standard therapy for heart failure every 4 weeks for a total of 6 doses.

| | |
|---|---|
| Arm type | Placebo |
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection/infusion in pre-filled syringe |
| Routes of administration | Intravenous use |

Dosage and administration details:

Matching placebo (0.9 percent sodium chloride solution) was administered intravenously in addition to the standard therapy for heart failure every 4 weeks for a total of 6 doses.

| | |
|---|---|
| **Arm title** | COR-1 20 mg |

Arm description:

COR-1 (JNJ-54452840) was administered at a dose of 20 milligram (mg) intravenously in addition to the standard therapy for heart failure every 4 weeks for a total of 6 doses.

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | COR-1 |
| Investigational medicinal product code | |
| Other name | JNJ-54452840 |
| Pharmaceutical forms | Solution for injection/infusion in pre-filled syringe |
| Routes of administration | Intravenous use |

Dosage and administration details:

COR-1 (JNJ-54452840) was administered at a dose of 20 milligrams (mg) intravenously in addition to the standard therapy for heart failure every 4 weeks for a total of 6 doses.

| | |
|---|---|
| **Arm title** | COR-1 80 mg |

Arm description:

COR-1 was administered at a dose of 80 milligram (mg) intravenously in addition to the standard therapy for heart failure every 4 weeks for a total of 6 doses.

| | |
|---|---|
| Arm type | Experimental |

| | |
|---|---|
| Investigational medicinal product name | COR-1 |
| Investigational medicinal product code | |
| Other name | JNJ-54452840 |
| Pharmaceutical forms | Solution for injection/infusion in pre-filled syringe |
| Routes of administration | Intravenous use |

Dosage and administration details:

COR-1 (JNJ-54452840) was administered at a dose of 80 milligrams (mg) intravenously in addition to the standard therapy for heart failure every 4 weeks for a total of 6 doses.

| | |
|---|---|
| **Arm title** | COR-1 160 mg |

Arm description:

COR-1 was administered at a dose of 160 milligram (mg) intravenously in addition to the standard therapy for heart failure every 4 weeks for a total of 6 doses.

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | COR-1 |
| Investigational medicinal product code | |
| Other name | JNJ-54452840 |
| Pharmaceutical forms | Solution for injection/infusion in pre-filled syringe |
| Routes of administration | Intravenous use |

Dosage and administration details:

COR-1 was administered at a dose of160 milligram (mg) intravenously in addition to the standard therapy for heart failure every 4 weeks for a total of 6 doses.

| **Number of subjects in period 1** | Placebo | COR-1 20 mg | COR-1 80 mg |
|---|---|---|---|
| Started | 10 | 8 | 6 |
| Completed | 6 | 4 | 2 |
| Not completed | 4 | 4 | 4 |
| Adverse event, serious fatal | - | - | - |
| Consent withdrawn by subject | 1 | 2 | 1 |
| Adverse event, non-fatal | - | - | 1 |
| Other | - | - | 2 |
| Protocol Violation | 2 | 1 | - |
| Adverse event, serious non-fatal | 1 | 1 | - |

| **Number of subjects in period 1** | COR-1 160 mg |
|---|---|
| Started | 12 |
| Completed | 5 |
| Not completed | 7 |
| Adverse event, serious fatal | 1 |
| Consent withdrawn by subject | 1 |
| Adverse event, non-fatal | - |
| Other | - |
| Protocol Violation | 3 |
| Adverse event, serious non-fatal | 2 |

## Baseline characteristics

| Reporting groups | |
|---|---|
| Reporting group title | Placebo |
| Reporting group description: | |
| Matching placebo (0.9 percent sodium chloride solution) was administered intravenously in addition to the standard therapy for heart failure every 4 weeks for a total of 6 doses. | |
| Reporting group title | COR-1 20 mg |
| Reporting group description: | |
| COR-1 (JNJ-54452840) was administered at a dose of 20 milligram (mg) intravenously in addition to the standard therapy for heart failure every 4 weeks for a total of 6 doses. | |
| Reporting group title | COR-1 80 mg |
| Reporting group description: | |
| COR-1 was administered at a dose of 80 milligram (mg) intravenously in addition to the standard therapy for heart failure every 4 weeks for a total of 6 doses. | |
| Reporting group title | COR-1 160 mg |
| Reporting group description: | |
| COR-1 was administered at a dose of 160 milligram (mg) intravenously in addition to the standard therapy for heart failure every 4 weeks for a total of 6 doses. | |

| Reporting group values | Placebo | COR-1 20 mg | COR-1 80 mg |
|---|---|---|---|
| Number of subjects | 10 | 8 | 6 |
| Title for AgeCategorical<br>Units: subjects | | | |
| Children (2-11 years) | 0 | 0 | 0 |
| Adolescents (12-17 years) | 0 | 0 | 0 |
| Adults (18-64 years) | 7 | 6 | 3 |
| From 65 to 84 years | 3 | 2 | 3 |
| 85 years and over | 0 | 0 | 0 |
| Title for AgeContinuous<br>Units: years | | | |
| arithmetic mean | 59.4 | 57.5 | 62 |
| standard deviation | ± 9.61 | ± 10.92 | ± 13.59 |
| Title for Gender<br>Units: subjects | | | |
| Female | 3 | 2 | 1 |
| Male | 7 | 6 | 5 |

| Reporting group values | COR-1 160 mg | Total | |
|---|---|---|---|
| Number of subjects | 12 | 36 | |
| Title for AgeCategorical<br>Units: subjects | | | |
| Children (2-11 years) | 0 | 0 | |
| Adolescents (12-17 years) | 0 | 0 | |
| Adults (18-64 years) | 7 | 23 | |
| From 65 to 84 years | 5 | 13 | |
| 85 years and over | 0 | 0 | |
| Title for AgeContinuous<br>Units: years | | | |
| arithmetic mean | 59.8 | | |

| | | | |
|---|---|---|---|
| standard deviation | ± 11.88 | - | |

| | | | |
|---|---|---|---|
| Title for Gender<br>Units: subjects | | | |
| Female | 2 | 8 | |
| Male | 10 | 28 | |

## End points

### End points reporting groups

| Reporting group title | Placebo |
|---|---|
| Reporting group description: | |
| Matching placebo (0.9 percent sodium chloride solution) was administered intravenously in addition to the standard therapy for heart failure every 4 weeks for a total of 6 doses. | |
| Reporting group title | COR-1 20 mg |
| Reporting group description: | |
| COR-1 (JNJ-54452840) was administered at a dose of 20 milligram (mg) intravenously in addition to the standard therapy for heart failure every 4 weeks for a total of 6 doses. | |
| Reporting group title | COR-1 80 mg |
| Reporting group description: | |
| COR-1 was administered at a dose of 80 milligram (mg) intravenously in addition to the standard therapy for heart failure every 4 weeks for a total of 6 doses. | |
| Reporting group title | COR-1 160 mg |
| Reporting group description: | |
| COR-1 was administered at a dose of 160 milligram (mg) intravenously in addition to the standard therapy for heart failure every 4 weeks for a total of 6 doses. | |

### Primary: Change From Baseline in Left Ventricular Ejection Fraction (LVEF) at Month 6

| End point title | Change From Baseline in Left Ventricular Ejection Fraction (LVEF) at Month 6[1] |
|---|---|
| End point description: | |
| The LVEF is a fraction of blood (in percent) pumped out of the left ventricle of the heart (the main pumping chamber). Ejection fraction percentages greater than (>) 55% are considered normal. It wasmeasured by biplane echocardiography (central assessment). | |
| End point type | Primary |
| End point timeframe: | |
| Baseline and Month 6 | |

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Inferential Statistical analysis was not reported.

| End point values | Placebo | COR-1 20 mg | COR-1 80 mg | COR-1 160 mg |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 10 | 8 | 6 | 12 |
| Units: participants | | | | |
| arithmetic mean (standard deviation) | | | | |
| Baseline | 35.4 (± 11.72) | 29.4 (± 12.6) | 35 (± 13.42) | 32.4 (± 10.77) |
| Change at Month 6 | -1.6 (± 5.94) | 0.8 (± 5.55) | 5.4 (± 10.11) | -0.9 (± 3.09) |

### Statistical analyses

No statistical analyses for this end point

## Primary: Change From Baseline in Local Left Ventricular Ejection Fraction (LVEF) at Month 9

| End point title | Change From Baseline in Local Left Ventricular Ejection Fraction (LVEF) at Month 9[2] |
|---|---|

End point description:

The LVEF is a measure of how much blood is pumped out of the left ventricle of the heart (the main pumping chamber). Ejection fraction percentages greater than (>) 55% are considered normal. It was measured by biplane echocardiography (local assessment).

| End point type | Primary |
|---|---|

End point timeframe:

Baseline and Month 9

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses for this end point.

| End point values | Placebo | COR-1 20 mg | COR-1 80 mg | COR-1 160 mg |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 10 | 8 | 6 | 12 |
| Units: participants | | | | |
| arithmetic mean (standard deviation) | | | | |
| Baseline | 32.6 (± 5.78) | 33.6 (± 9.77) | 35.3 (± 8.57) | 32.5 (± 9.27) |
| Change at Month 9 | -0.8 (± 4.39) | -1.9 (± 5.99) | 3.8 (± 4.02) | -1.8 (± 3.13) |

### Statistical analyses

No statistical analyses for this end point

## Primary: Change From Baseline in N-Terminal Pro B-Type Natriuretic Peptide (NTProBNP) Level at Month 6

| End point title | Change From Baseline in N-Terminal Pro B-Type Natriuretic Peptide (NTProBNP) Level at Month 6[3] |
|---|---|

End point description:

The NT-ProBNP is a biomarker (a biologic molecule) that has been shown to predict cardiac events.

| End point type | Primary |
|---|---|

End point timeframe:

Baseline and Month 6

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses for this end point.

| End point values | Placebo | COR-1 20 mg | COR-1 80 mg | COR-1 160 mg |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 10 | 8 | 6 | 12 |
| Units: Participants | | | | |
| arithmetic mean (standard deviation) | | | | |
| Baseline | 5678 (± 9347.1) | 2215.9 (± 1692.1) | 971.4 (± 665.1) | 2299.4 (± 2024.1) |
| Change at Month 6 | -805.7 (± 1241) | 1363.4 (± 3948.7) | 392.8 (± 295.7) | 1109.6 (± 2130.6) |

### Statistical analyses

No statistical analyses for this end point

## Secondary: Change From Baseline in Central Transmitral Flow Velocity Time Integral (VTI) at Month 6

| End point title | Change From Baseline in Central Transmitral Flow Velocity Time Integral (VTI) at Month 6 |
|---|---|

End point description:

Transmitral flow VTI measures how blood flows through the heart. This was measured by echocardiogram. Most of the values for transmitral flow VTI were not provided in the reports from central core echocardiographic laboratory due to technical reasons. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure. Standard deviation was not reported since only 1 participant was evaluable for this arm group i.e Change at Month 6.

| End point type | Secondary |
|---|---|

End point timeframe:

Baseline and Month 6

| End point values | Placebo | COR-1 20 mg | COR-1 80 mg | COR-1 160 mg |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 2 | 1 | 0[4] | 0[5] |
| Units: Participants | | | | |
| arithmetic mean (standard deviation) | | | | |
| Baseline | 45 (± 31.11) | 21 (± 0.99999) | () | () |
| Change at Month 6 | 0 (± 0) | 0 (± 0.99999) | () | () |

Notes:

[4] - None of the participant was evaluable.

[5] - None of the participant was evaluable.

### Statistical analyses

No statistical analyses for this end point

## Secondary: Change From Baseline in Central Tissue E-Wave Doppler Mitral Annular Velocity at Month 6

| End point title | Change From Baseline in Central Tissue E-Wave Doppler Mitral Annular Velocity at Month 6 |
|---|---|

End point description:

Tissue doppler mitral annular velocity is a measure of how well the heart fills with blood. This was measured by echocardiogram. Most of the values for E-wave were not provided in the reports from central core echocardiographic laboratory due to technical reasons. Standard deviation was not reported since only 1 participant was evaluable for this arm group i.e COR-1 80 mg.

| End point type | Secondary |
|---|---|

End point timeframe:

Baseline and Month 6

| End point values | Placebo | COR-1 20 mg | COR-1 80 mg | COR-1 160 mg |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 5 | 5 | 1 | 4 |
| Units: Participants | | | | |
| arithmetic mean (standard deviation) | | | | |
| Baseline | 5.6 (± 1.52) | 5.2 (± 1.1) | 4 (± 99999) | 5.8 (± 1.71) |
| Change at Month 6 | -0.2 (± 0.45) | 0 (± 0) | 0 (± 99999) | 0 (± 0) |

**Statistical analyses**

No statistical analyses for this end point

**Secondary: Change From Baseline in Distance Walked During Six-minute Walk Test at Month 6**

| End point title | Change From Baseline in Distance Walked During Six-minute Walk Test at Month 6 |
|---|---|

End point description:

A standardized 6-minute walk test was performed and the distance covered in 6 minutes was measured.

| End point type | Secondary |
|---|---|

End point timeframe:

Baseline and Month 6

| End point values | Placebo | COR-1 20 mg | COR-1 80 mg | COR-1 160 mg |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 10 | 8 | 6 | 12 |
| Units: Participants | | | | |
| arithmetic mean (standard deviation) | | | | |
| Baseline | 421.1 (± 113.29) | 451.1 (± 51.2) | 395.2 (± 81.3) | 420.7 (± 109.77) |
| Change at Month 6 | 38.7 (± 63.11) | -8.7 (± 104.35) | 12.8 (± 57.7) | 2.4 (± 41.01) |

**Statistical analyses**

No statistical analyses for this end point

**Secondary: Number of Participants With New York Heart Association (NYHA) Classification of Disease Progression**

| End point title | Number of Participants With New York Heart Association (NYHA) Classification of Disease Progression |
|---|---|

End point description:

Disease progression (morbidity) was measured by the NYHA classification. The NYHA classification assesses the severity of symptoms of heart failure as judged by the investigator and is comprised of 4 stages. Stage I- No symptoms/limitation in ordinary physical activity (for example, shortness of breath when walking, climbing stairs); Stage II-Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity; Stage III- Marked limitation in activity due to symptoms, even during less-than-ordinary activity, (for example, walking short distances [20-100 m]), comfortable only

| End point type | Secondary |
|---|---|

End point timeframe:

Baseline and Month 6

| **End point values** | Placebo | COR-1 20 mg | COR-1 80 mg | COR-1 160 mg |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 10 | 8 | 6 | 12 |
| Units: number of participants | | | | |
| Baseline: Stage II (n= 10, 8, 6, 12) | 7 | 8 | 3 | 7 |
| Baseline: Stage III (n= 10, 8, 6, 12) | 3 | 0 | 3 | 5 |
| Month 6: Stage I (n= 7, 7, 5, 8) | 1 | 1 | 0 | 0 |
| Month 6: Stage II (n= 7, 7, 5, 8) | 3 | 4 | 3 | 6 |
| Month 6: Stage III (n= 7, 7, 5, 8) | 3 | 2 | 2 | 2 |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change From Baseline in Minnesota Living With Heart Failure Questionnaire Score at Month 6

| End point title | Change From Baseline in Minnesota Living With Heart Failure Questionnaire Score at Month 6 |
|---|---|

End point description:

Minnesota living with heart failure questionnaire is a self-administered, disease-specific measure of health related quality of life (QOL) that assesses participant's perceptions of the influence of heart failure on physical, socioeconomic and psychological aspects of life. Participants responded to 21 items using a six-point response scale (0-5). The total summary score can range from 0-105 with a lower score reflecting better heart failure related QOL.

| End point type | Secondary |
|---|---|

End point timeframe:

Baseline and Month 6

| **End point values** | Placebo | COR-1 20 mg | COR-1 80 mg | COR-1 160 mg |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 7 | 7 | 5 | 11 |
| Units: Participants | | | | |
| arithmetic mean (standard deviation) | | | | |
| Baseline | 23.7 (± 11.57) | 21.4 (± 12.9) | 33.2 (± 23.9) | 25.9 (± 25.27) |
| Change at Month 6 | 3.3 (± 10.7) | 3.3 (± 16.26) | 1.8 (± 9.5) | 2.4 (± 20.5) |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change From Baseline in Holter Electrocardiography (ECG) Parameters (Heart Rate) at Month 6

| End point title | Change From Baseline in Holter Electrocardiography (ECG) Parameters (Heart Rate) at Month 6 |
|---|---|

End point description:

A Holter monitor is a portable device which monitors the electrical activity (electrocardiography) of the heart. Mean heart rate, maximum heart rate and minimum heart rate were evaluated. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.

| End point type | Secondary |
|---|---|

End point timeframe:

Baseline and Month 6

| End point values | Placebo | COR-1 20 mg | COR-1 80 mg | COR-1 160 mg |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 7 | 7 | 5 | 11 |
| Units: Participants | | | | |
| arithmetic mean (standard deviation) | | | | |
| Baseline: Mean Heart Rate | 74.6 (± 7) | 76.9 (± 10.92) | 84.2 (± 11.43) | 75.3 (± 8.59) |
| Change at Month 6: Mean Heart Rate | 1.3 (± 6.68) | -0.9 (± 3.63) | -5.8 (± 10.18) | 1.4 (± 6.97) |
| Baseline: Maximum Heart Rate | 126.4 (± 18.28) | 130.3 (± 33.26) | 123 (± 15.26) | 125.1 (± 35.23) |
| Change at Month 6: Maximum Heart | -0.8 (± 15.24) | 5.4 (± 40.15) | 0 (± 25.3) | -2 (± 31.56) |
| Baseline: Minimum Heart Rate | 51.6 (± 11.54) | 59.3 (± 13.12) | 66 (± 4.16) | 58.7 (± 6.65) |
| Change at Month 6: Minimum Heart | 0.5 (± 3.39) | 0.1 (± 3.93) | -7.8 (± 4.5) | -2.3 (± 10.09) |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Participants With Holter Electrocardiography (ECG) Parameters

| End point title | Number of Participants With Holter Electrocardiography (ECG) Parameters |
|---|---|

End point description:

| End point type | Secondary |
|---|---|

End point timeframe:
Baseline and Month 6

| **End point values** | Placebo | COR-1 20 mg | COR-1 80 mg | COR-1 160 mg |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 7 | 7 | 5 | 11 |
| Units: number of participants | | | | |
| Baseline: No block | 7 | 7 | 5 | 7 |
| Baseline: AV block I | 0 | 0 | 0 | 3 |
| Baseline: AV block II | 0 | 0 | 0 | 0 |
| Baseline: AV block III | 0 | 0 | 0 | 0 |
| Baseline: Sinus rhythm | 5 | 4 | 4 | 7 |
| Baseline: Atrial fibrillation | 0 | 0 | 0 | 0 |
| Baseline:Atrial fibrillation-paroxysmal/persisten | 2 | 1 | 1 | 1 |
| Baseline: Other | 0 | 2 | 0 | 2 |
| Baseline; AV junctional, 0-240/24h | 5 | 6 | 4 | 6 |
| Baseline: AV junctional, 241-1000/24h | 2 | 0 | 0 | 3 |
| Baseline: AV junctional, 1001-2400/24h | 0 | 0 | 1 | 1 |
| Baseline: Ventricular, 0-240/24h | 1 | 1 | 1 | 4 |
| Baseline: Ventricular, 241-1000/24h | 2 | 2 | 2 | 1 |
| Baseline: Ventricular, 1001-2400/24h | 4 | 3 | 2 | 5 |
| Baseline: 0 No VES | 0 | 1 | 0 | 0 |
| Baseline: I Occasional individual VES (<30/h) | 3 | 0 | 1 | 4 |
| Baseline: II Frequent VES (>30/h) | 0 | 2 | 0 | 0 |
| Baseline: IIIa Polymorphous VES | 1 | 0 | 0 | 1 |
| Baseline: IIIb Ventricular bigeminy | 0 | 0 | 0 | 1 |
| Baseline: IVa Couplets, repetitive VES | 1 | 2 | 2 | 1 |
| Baseline: IVb Runs, repetitive VES | 2 | 2 | 1 | 3 |
| Baseline: V Early occurring VES(R-on T phenomenon) | 0 | 0 | 0 | 0 |
| Baseline: II, IIIa, IVa, IVb | 0 | 0 | 1 | 0 |
| Baseline: Normal | 2 | 0 | 2 | 1 |
| Baseline: Abnormal, NCS | 5 | 5 | 1 | 8 |
| Baseline: Abnormal, CS | 0 | 2 | 2 | 1 |
| Month 6: No block | 6 | 7 | 5 | 5 |
| Month 6: AV block I | 0 | 0 | 0 | 1 |
| Month 6: AV block II | 0 | 0 | 0 | 1 |
| Month 6: AV block III | 0 | 0 | 0 | 0 |
| Month 6: Sinus rhythm | 2 | 4 | 3 | 6 |
| Month 6: Atrial fibrillation | 0 | 0 | 0 | 0 |
| Month 6: Atrial fibrillation paroxysma/persistent | 2 | 2 | 1 | 0 |
| Month 6: Other | 2 | 1 | 1 | 1 |
| Month 6: AV junctional, 0-240/24h | 5 | 5 | 4 | 4 |
| Month 6: AV junctional, 241-1000/24h | 1 | 2 | 1 | 1 |
| Month 6: AV junctional, 1001-2400/24h | 0 | 0 | 0 | 2 |
| Month 6: Ventricular, 0-240/24h | 2 | 2 | 1 | 2 |
| Month 6: Ventricular, 241-1000/24h | 0 | 2 | 1 | 1 |

| | | | | |
|---|---|---|---|---|
| Month 6: Ventricular, 1001-2400/24h | 4 | 3 | 3 | 4 |
| Month 6: 0 No VES | 0 | 1 | 0 | 0 |
| Month 6: I Occasional individual VES (<30/h) | 2 | 0 | 2 | 2 |
| Month 6: II Frequent VES (>30/h) | 0 | 0 | 0 | 1 |
| Month 6: IIIa Polymorphous VES | 2 | 3 | 1 | 1 |
| Month 6: IVa Couplets, repetitive VES | 1 | 1 | 0 | 1 |
| Month 6: IVb Runs, repetitive VES | 1 | 1 | 1 | 2 |
| Month 6: V Early occurring VES (R-on Tphenomenon) | 0 | 0 | 0 | 0 |
| Month 6: II, IIIa, IVa, IVb | 0 | 1 | 1 | 0 |
| Month 6: Normal | 0 | 0 | 1 | 1 |
| Month 6: Abnormal, NCS | 6 | 6 | 3 | 5 |
| Month 6: Abnormal, CS | 0 | 1 | 1 | 1 |

## Statistical analyses

No statistical analyses for this end point

## Adverse events

| Adverse events information | |
|---|---|
| Timeframe for reporting adverse events: | |
| Timeframe for AE | |
| Assessment type | Non-systematic |
| **Dictionary used** | |
| Dictionary name | MedDRA |
| Dictionary version | 16.0 |
| **Reporting groups** | |
| Reporting group title | Placebo |
| Reporting group description: | |
| Placebo intravenously once per visit | |
| Reporting group title | 160 mg COR-1 |
| Reporting group description: - | |
| Reporting group title | 80 mg COR-1 |
| Reporting group description: - | |
| Reporting group title | 20 mg COR-1 |
| Reporting group description: - | |

| Serious adverse events | Placebo | 160 mg COR-1 | 80 mg COR-1 |
|---|---|---|---|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 6 / 11 (54.55%) | 1 / 5 (20.00%) |
| number of deaths (all causes) | 0 | 1 | 0 |
| number of deaths resulting from adverse events | | | |
| Investigations | | | |
| Ejection Fraction Decreased | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 1 / 11 (9.09%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Weight Increased | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 0 / 11 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Ovarian Cancer | | | |
| alternative assessment type: Systematic | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 11 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Prostate Cancer | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 1 / 11 (9.09%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac disorders | | | |
| Cardiac Failure | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 2 / 11 (18.18%) | 1 / 5 (20.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 3 | 0 / 6 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| Cardiogenic Shock | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 1 / 11 (9.09%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| Heart Valve Incompetence | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 1 / 11 (9.09%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Sinus Arrest | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 1 / 11 (9.09%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Surgical and medical procedures | | | |
| Haemodialysis | | | |
| alternative assessment type: Systematic | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 7 (0.00%) | 1 / 11 (9.09%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| Nervous system disorders | | | |
| Loss of Consciousness | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 1 / 11 (9.09%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Presyncope | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 1 / 11 (9.09%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| General disorders and administration site conditions | | | |
| Cardiac Death | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 1 / 11 (9.09%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Dyspnoea | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 0 / 11 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pulmonary Oedema | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 1 / 11 (9.09%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| Psychiatric disorders | | | |
| Mental Disorder | | | |

| | | | |
|---|---|---|---|
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 1 / 11 (9.09%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 4 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal and urinary disorders | | | |
| Renal Failure | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 1 / 11 (9.09%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| Infections and infestations | | | |
| Lobar Pneumonia | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 1 / 11 (9.09%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 1 / 11 (9.09%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |

| **Serious adverse events** | 20 mg COR-1 | | |
|---|---|---|---|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | | |
| number of deaths (all causes) | 0 | | |
| number of deaths resulting from adverse events | | | |
| Investigations | | | |
| Ejection Fraction Decreased | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Weight Increased | | | |
| alternative assessment type: Systematic | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 7 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Ovarian Cancer | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Prostate Cancer | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Cardiac disorders | | | |
| Cardiac Failure | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Cardiogenic Shock | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Heart Valve Incompetence | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Sinus Arrest | | | |
| alternative assessment type: Systematic | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 7 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Surgical and medical procedures | | | |
| Haemodialysis | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Nervous system disorders | | | |
| Loss of Consciousness | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Presyncope | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| General disorders and administration site conditions | | | |
| Cardiac Death | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Dyspnoea | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Pulmonary Oedema | | | |

| | | | |
|---|---|---|---|
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Psychiatric disorders | | | |
| Mental Disorder | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Renal and urinary disorders | | | |
| Renal Failure | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Infections and infestations | | | |
| Lobar Pneumonia | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Pneumonia | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |

Frequency threshold for reporting non-serious adverse events: 5 %

| **Non-serious adverse events** | Placebo | 160 mg COR-1 | 80 mg COR-1 |
|---|---|---|---|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 4 / 7 (57.14%) | 8 / 11 (72.73%) | 5 / 5 (100.00%) |
| Vascular disorders | | | |

| | | | |
|---|---|---|---|
| Venous Insufficiency | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 0 / 11 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Surgical and medical procedures | | | |
| Wisdom Teeth Removal | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 1 / 11 (9.09%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| General disorders and administration site conditions | | | |
| Asthenia | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 1 / 11 (9.09%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Chest Pain | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 1 / 11 (9.09%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Fatigue | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 1 / 11 (9.09%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Injection Site Haematoma | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 0 / 11 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| General Physical Health Deterioration | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 1 / 11 (9.09%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Oedema Peripheral | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 0 / 11 (0.00%) | 2 / 5 (40.00%) |
| occurrences (all) | 1 | 0 | 2 |
| Pyrexia | | | |

| | | | |
|---|---|---|---|
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 1 / 11 (9.09%) | 1 / 5 (20.00%) |
| occurrences (all) | 1 | 2 | 1 |
| Reproductive system and breast disorders | | | |
| Gynaecomastia | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 1 / 11 (9.09%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Cough | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 2 / 11 (18.18%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Rhonchi | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 0 / 11 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Psychiatric disorders | | | |
| Hallucination | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 1 / 11 (9.09%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Mental Disorder | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 1 / 11 (9.09%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Investigations | | | |
| Blood Creatine Increased | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 11 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood Potassium Increased | | | |
| alternative assessment type: Systematic | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 7 (0.00%) | 1 / 11 (9.09%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Blood Pressure Decreased | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 11 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Carotid Bruit | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 11 (0.00%) | 1 / 5 (20.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Glomerular Filtration Rate Abnormal | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 11 (0.00%) | 1 / 5 (20.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Heart Rate Increased | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 1 / 11 (9.09%) | 1 / 5 (20.00%) |
| occurrences (all) | 1 | 2 | 1 |
| Hepatic Enzyme Increased | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 11 (0.00%) | 1 / 5 (20.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Prostatic Specific Antigen Increased | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 1 / 11 (9.09%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Weight Increased | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 0 / 11 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Injury, poisoning and procedural complications | | | |
| Excoriation | | | |
| alternative assessment type: Systematic | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 7 (14.29%) | 0 / 11 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Face Injury | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 0 / 11 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Fall | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 0 / 11 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Overdose | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 0 / 11 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Traumatic Haematoma | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 0 / 11 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Cardiac disorders | | | |
| Arrhythmia | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 11 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Bradycardia | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 11 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cardiac Failure | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 0 / 11 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Palpitations | | | |
| alternative assessment type: Systematic | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 11 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sinus Bradycardia | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 11 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tachycardia | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 11 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ventricular Extrasystoles | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 1 / 11 (9.09%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Nervous system disorders | | | |
| Aura | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 1 / 11 (9.09%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Dysgeusia | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 1 / 11 (9.09%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Dizziness | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 11 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Paraesthesia | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 1 / 11 (9.09%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Headache | | | |
| alternative assessment type: Systematic | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 7 (14.29%) | 1 / 11 (9.09%) | 0 / 5 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Presyncope | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 11 (0.00%) | 1 / 5 (20.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Sciatica | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 1 / 11 (9.09%) | 0 / 5 (0.00%) |
| occurrences (all) | 1 | 2 | 0 |
| Syncope | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 0 / 11 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |
| Ear and labyrinth disorders | | | |
| Vertigo | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 1 / 11 (9.09%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Gastrointestinal disorders | | | |
| Abdominal Pain Lower | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 11 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Abdominal Pain Upper | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 0 / 11 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Anal Inflammation | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 1 / 11 (9.09%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Diarrhoea | | | |
| alternative assessment type: Systematic | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 7 (0.00%) | 2 / 11 (18.18%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Nausea | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 1 / 11 (9.09%) | 0 / 5 (0.00%) |
| occurrences (all) | 1 | 2 | 0 |
| Toothache | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 11 (0.00%) | 1 / 5 (20.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Hepatobiliary disorders | | | |
| Hepatomegaly | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 1 / 11 (9.09%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Skin and subcutaneous tissue disorders | | | |
| Erythema | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 11 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Renal and urinary disorders | | | |
| Renal Impairment | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 0 / 11 (0.00%) | 1 / 5 (20.00%) |
| occurrences (all) | 1 | 0 | 1 |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 1 / 11 (9.09%) | 0 / 5 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Back Pain | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 0 / 11 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Joint Swelling | | | |

| | | | |
|---|---|---|---|
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 11 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Musculoskeletal Pain | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 0 / 11 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Pain in Extremity | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 0 / 11 (0.00%) | 1 / 5 (20.00%) |
| occurrences (all) | 1 | 0 | 1 |
| Infections and infestations | | | |
| Acute Tonsillitis | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 0 / 11 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Cystitis | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 0 / 11 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Influenza | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 1 / 11 (9.09%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Nasopharyngitis | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 1 / 11 (9.09%) | 2 / 5 (40.00%) |
| occurrences (all) | 0 | 2 | 2 |
| Oral Herpes | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 11 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Respiratory Tract Infection | | | |
| alternative assessment type: Systematic | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 7 (14.29%) | 0 / 11 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Rhinitis | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 11 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sinusitis | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 1 / 11 (9.09%) | 1 / 5 (20.00%) |
| occurrences (all) | 0 | 1 | 1 |
| Staphylococcal Infection | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 11 (0.00%) | 1 / 5 (20.00%) |
| occurrences (all) | 0 | 0 | 3 |
| Metabolism and nutrition disorders | | | |
| Decreased Appetite | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 11 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gout | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 11 (0.00%) | 1 / 5 (20.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Hyponatraemia | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 11 (0.00%) | 1 / 5 (20.00%) |
| occurrences (all) | 0 | 0 | 1 |

| **Non-serious adverse events** | 20 mg COR-1 | | |
|---|---|---|---|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 7 / 7 (100.00%) | | |
| Vascular disorders | | | |
| Venous Insufficiency | | | |
| alternative assessment type: Systematic | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 7 (0.00%) | | |
| occurrences (all) | 0 | | |
| Surgical and medical procedures | | | |
| Wisdom Teeth Removal | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | | |
| occurrences (all) | 0 | | |
| General disorders and administration site conditions | | | |
| Asthenia | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | | |
| occurrences (all) | 0 | | |
| Chest Pain | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | | |
| occurrences (all) | 0 | | |
| Fatigue | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | | |
| occurrences (all) | 0 | | |
| Injection Site Haematoma | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | | |
| occurrences (all) | 0 | | |
| General Physical Health Deterioration | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | | |
| occurrences (all) | 0 | | |
| Oedema Peripheral | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | | |
| occurrences (all) | 0 | | |
| Pyrexia | | | |
| alternative assessment type: Systematic | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 7 (0.00%) | | |
| occurrences (all) | 0 | | |
| Reproductive system and breast disorders | | | |
| Gynaecomastia | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | | |
| occurrences (all) | 0 | | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Cough | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | | |
| occurrences (all) | 1 | | |
| Rhonchi | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | | |
| occurrences (all) | 0 | | |
| Psychiatric disorders | | | |
| Hallucination | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | | |
| occurrences (all) | 0 | | |
| Mental Disorder | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | | |
| occurrences (all) | 0 | | |
| Investigations | | | |
| Blood Creatine Increased | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | | |
| occurrences (all) | 1 | | |
| Blood Potassium Increased | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | | |
| occurrences (all) | 1 | | |
| Blood Pressure Decreased | | | |

| | | | |
|---|---|---|---|
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | | |
| occurrences (all) | 1 | | |
| Carotid Bruit | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | | |
| occurrences (all) | 0 | | |
| Glomerular Filtration Rate Abnormal | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | | |
| occurrences (all) | 0 | | |
| Heart Rate Increased | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | | |
| occurrences (all) | 1 | | |
| Hepatic Enzyme Increased | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | | |
| occurrences (all) | 0 | | |
| Prostatic Specific Antigen Increased | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | | |
| occurrences (all) | 0 | | |
| Weight Increased | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | | |
| occurrences (all) | 0 | | |
| Injury, poisoning and procedural complications | | | |
| Excoriation | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | | |
| occurrences (all) | 0 | | |
| Face Injury | | | |
| alternative assessment type: Systematic | | | |

| | | | | |
|---|---|---|---|---|
| subjects affected / exposed | 0 / 7 (0.00%) | | | |
| occurrences (all) | 0 | | | |
| Fall | | | | |
| alternative assessment type: Systematic | | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | | | |
| occurrences (all) | 0 | | | |
| Overdose | | | | |
| alternative assessment type: Systematic | | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | | | |
| occurrences (all) | 0 | | | |
| Traumatic Haematoma | | | | |
| alternative assessment type: Systematic | | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | | | |
| occurrences (all) | 0 | | | |
| Cardiac disorders | | | | |
| Arrhythmia | | | | |
| alternative assessment type: Systematic | | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | | | |
| occurrences (all) | 1 | | | |
| Bradycardia | | | | |
| alternative assessment type: Systematic | | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | | | |
| occurrences (all) | 1 | | | |
| Cardiac Failure | | | | |
| alternative assessment type: Systematic | | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | | | |
| occurrences (all) | 2 | | | |
| Palpitations | | | | |
| alternative assessment type: Systematic | | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | | | |
| occurrences (all) | 1 | | | |
| Sinus Bradycardia | | | | |
| alternative assessment type: Systematic | | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 7 (14.29%) | | |
| occurrences (all) | 1 | | |
| Tachycardia | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | | |
| occurrences (all) | 1 | | |
| Ventricular Extrasystoles | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | | |
| occurrences (all) | 0 | | |
| Nervous system disorders | | | |
| Aura | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | | |
| occurrences (all) | 0 | | |
| Dysgeusia | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | | |
| occurrences (all) | 0 | | |
| Dizziness | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | | |
| occurrences (all) | 1 | | |
| Paraesthesia | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | | |
| occurrences (all) | 0 | | |
| Headache | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | | |
| occurrences (all) | 0 | | |
| Presyncope | | | |
| alternative assessment type: Systematic | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 7 (0.00%) | | |
| occurrences (all) | 0 | | |
| Sciatica | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | | |
| occurrences (all) | 0 | | |
| Syncope | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | | |
| occurrences (all) | 0 | | |
| Ear and labyrinth disorders | | | |
| Vertigo | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | | |
| occurrences (all) | 0 | | |
| Gastrointestinal disorders | | | |
| Abdominal Pain Lower | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | | |
| occurrences (all) | 1 | | |
| Abdominal Pain Upper | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | | |
| occurrences (all) | 0 | | |
| Anal Inflammation | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | | |
| occurrences (all) | 0 | | |
| Diarrhoea | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | | |
| occurrences (all) | 0 | | |
| Nausea | | | |
| alternative assessment type: Systematic | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 7 (14.29%) | | |
| occurrences (all) | 2 | | |
| Toothache | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | | |
| occurrences (all) | 0 | | |
| Hepatobiliary disorders | | | |
| Hepatomegaly | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | | |
| occurrences (all) | 0 | | |
| Skin and subcutaneous tissue disorders | | | |
| Erythema | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | | |
| occurrences (all) | 2 | | |
| Renal and urinary disorders | | | |
| Renal Impairment | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | | |
| occurrences (all) | 0 | | |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | | |
| occurrences (all) | 0 | | |
| Back Pain | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | | |
| occurrences (all) | 0 | | |
| Joint Swelling | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | | |
| occurrences (all) | 2 | | |
| Musculoskeletal Pain | | | |

| | | | |
|---|---|---|---|
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | | |
| occurrences (all) | 0 | | |
| Pain in Extremity | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | | |
| occurrences (all) | 0 | | |
| Infections and infestations | | | |
| Acute Tonsillitis | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | | |
| occurrences (all) | 0 | | |
| Cystitis | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | | |
| occurrences (all) | 0 | | |
| Influenza | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | | |
| occurrences (all) | 0 | | |
| Nasopharyngitis | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | | |
| occurrences (all) | 1 | | |
| Oral Herpes | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | | |
| occurrences (all) | 1 | | |
| Respiratory Tract Infection | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | | |
| occurrences (all) | 0 | | |
| Rhinitis | | | |
| alternative assessment type: Systematic | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 7 (14.29%) | | |
| occurrences (all) | 1 | | |
| Sinusitis | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | | |
| occurrences (all) | 1 | | |
| Staphylococcal Infection | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | | |
| occurrences (all) | 0 | | |
| Metabolism and nutrition disorders | | | |
| Decreased Appetite | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | | |
| occurrences (all) | 1 | | |
| Gout | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | | |
| occurrences (all) | 0 | | |
| Hyponatraemia | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | | |
| occurrences (all) | 0 | | |

## More information

## Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|---|---|
| 17 May 2011 | Amendment Version 2.0 addressed and/or corrected procedural issues only. It was written by CorImmun and finalized before any subjects were enrolled in the study. |
| 28 July 2011 | Amendment Version 3.0 was finalized by CorImmun before any subjects were randomized in the study and it addressed concerns raised by the Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM). At the request of BfArM, the protocol was amended to edit the exclusion criteria and to add cytokine analysis, additional laboratory analysis at 2 visits, and additional safety measures, including the management of allergic reactions. |
| 28 June 2012 | Amendment Version 4.0 was written by JRD to document the acquisition of CorImmun by Janssen-Cilag GmbH as of 27 June 2012. In addition to editorial changes for clarity, major changes to the protocol included the modification of the study design to a pilot study as well as a decrease in the sample size to up to 60 randomized subjects. These changes were implemented as the original study was unable to meet the study objectives even if enrollment were to have continued to the planned sample size of 160 evaluable subjects. |
| 15 October 2012 | Major changes in Amendment Version 5.0 included the unblinding of the sponsor (CorImmun delegated this responsibility to JRD) as well as the discontinuation of further enrollment. These changes were introduced to give Janssen Research & Development LLC the opportunity to facilitate the planning of future studies by allowing for the proactive incorporation of any information obtained from this study. In addition, the follow-up visit 12-months after the treatment period was deleted and a requirement for cardiac monitoring (eg, telemetry) beginning a minimum of 15 minutes before the start of dosing to a minimum of 1 hour after dosing was added. |

Notes:

## Interruptions (globally)

Were there any global interruptions to the trial? No

## Limitations and caveats

None reported